Pharma Company, Sanofi India’s board of directors have recommended a special dividend of ₹ 193 against a face value of ₹ 10 per equity share (1930% of its face value), for the financial year ending December 2022. The company’s board announced this decision after its scheduled board meeting held on July 26, 2022.
“The Board of Directors of the Company at its Meeting held today has declared One-Time Special Interim Dividend of Rs. 193 per equity share of Rs. 10 each for the financial year ending 31st December 2022. The Meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 5.10 p.m. As informed earlier the Company has fixed 8th August 2022 as the record date for the purpose of payment of the One-Time Special Interim Dividend. The said dividend will be paid on or after 22nd August 2022, ” the company informed the stock exchanges.
The record date for the payment of the special dividend is August 8, 2022. The shares of the company will start trading ex-dividend on August 05, 2022, since the markets will remain closed on August 06 and August 07 due to the weekend. The dividend will be paid on or after August 22, 2022.
Earlier on April 12, Sanofi India’s shares had started trading ex-dividend as the company had declared a final dividend of ₹ 181 and a special dividend of ₹ 309 per equity share. There are a few months for the calendar year to come to an end, but the company has already announced ₹ 683 in dividends per equity share (₹ 193+ ₹ 309+ ₹ 109). The shares of the company closed at ₹ 6369.75 on Wednesday. At that price, the dividend yield of the company is 10.72%.
The company posted a net profit of ₹120.4 crores in the April to June quarter, down 32.47% as compared to ₹ 178.3 crores reported in the corresponding quarter last year. The company had reported a profit of ₹ 238.4 crores in the preceding quarter.
Written By Simran Bafna
Disclaimer
The content in this news article is not investment advice. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
